Four Global First-in-Class Drugs Approved on the Same Day in China

Note: The statistical data for this week is set to be finalized on Friday, with data from Saturday and Sunday carried over to the next week.

On March 27, the NMPA issued a large number of approvals, with several globally first-in-class drugs being approved in China.AstraZeneca and Amgen's Tezepelumab Injection Approved for Marketing，The two approved indications are asthma and chronic rhinosinusitis with nasal polyps, respectively.Tezepelumab is currently the world's only approved TSLP monoclonal antibody, with global sales nearing $2 billion in 2025.

GSK China's Demochicumab Approved for Marketing, used for the treatment of eosinophilic asthma,Demochizumab isThe world's first ultra-long-acting IL-5 biologic administered once every six months.

UCB's First-in-Class Dual-Target Drug BimekizumabTwo Indications Approved on the Same Day, Benefiting Patients with Psoriasis and Hidradenitis Suppurativa.

In China, Chongqing Yuyan Pharmaceutical Co., Ltd. has been approved.New Anti-Wrinkle Drug，The World's First Recombinant Botulinum Toxin Type A in the Field of Botulinum Toxins, 2023,Huadong MedicineReached a commercial cooperation agreement with Chongqing Yuyan Pharmaceutical Co., Ltd.,Huadong Medicine Co., Ltd. owns partial rights.

Daiichi Sankyo's injectable drug, Trastuzumab Deruxtecan, is quite interesting. On Wednesday, a notification was received, and by Friday, a new indication was approved. Two outcomes within a week, with the approved indication being the 7th in China.

In terms of generic drugs,Finerenone tablets have gained another qualified manufacturer, with two companies currently marketing generic versions, namely Hunan Huize andHunan Mingrui.

Qilu Pharmaceutical has secured another first generic, originally developed by Sanofi.Belumosudil Mesylate Tablets, used for the treatment of adult and pediatric patients aged 12 years and older with chronic graft-versus-host disease after failure of at least two systemic therapies, have been successfully developed and launched by Qilu Pharmaceutical.

↓ Scan the code to join the PharmExchange community group ↓

1、Marketing Authorization Review Conclusion

2. Marketing Application

3. Apply for Clinical Trials

4. Clinical Approval

↓⭐Follow PharmaNews, Insight into Industry Trends ↓

Submission/Corporate Cooperation/Content Communication:

Editor-in-Chief of PharmaTong Society—Huaji Meiren (Ww_150525)